{
  "schema_version": "1.0.0",
  "title": "ACC/AHA Guideline for Percutaneous Coronary Intervention",
  "organization": "American College of Cardiology / American Heart Association",
  "year": 2021,
  "version": "2021 Focused Update",
  "guideline_id": "ACC-AHA-PCI-2021",
  "metadata": {
    "doi": "10.1161/CIR.0000000000001027",
    "url": "https://www.acc.org/guidelines",
    "committee": "ACC/AHA Committee on Interventional Cardiology",
    "last_updated": "2021-12-20"
  },
  "indications": {
    "class_i": [
      {
        "indication": "PCI for STEMI",
        "description": "Primary PCI is indicated for patients with STEMI within 12 hours of symptom onset",
        "evidence_level": "Level A",
        "supporting_studies": ["NRMI", "NRMI-2", "GUSTO-IIb", "Primary Angioplasty in Myocardial Infarction Trial"],
        "time_frames": {
          "door_to_balloon": "<90 minutes",
          "first_medical_contact_to_device": "<120 minutes"
        }
      },
      {
        "indication": "PCI for NSTE-ACS",
        "description": "Early invasive strategy with PCI indicated for high-risk NSTE-ACS",
        "evidence_level": "Level A",
        "risk_factors": ["Elevated troponin", "ST changes", "Hemodynamic instability", "TIMI risk score >3"]
      },
      {
        "indication": "PCI for stable ischemic heart disease",
        "description": "PCI to improve survival in patients with extensive ischemia",
        "evidence_level": "Level B",
        "ischemia_threshold": ">10% ischemic myocardium"
      }
    ],
    "class_iia": [
      {
        "indication": "Chronic total occlusion PCI",
        "description": "PCI of CTO can be useful in selected patients with refractory angina or ischemia",
        "evidence_level": "Level B"
      },
      {
        "indication": "Multivessel PCI in cardiogenic shock",
        "description": "Multivessel PCI may be reasonable in cardiogenic shock",
        "evidence_level": "Level B-R"
      }
    ],
    "class_iii": [
      {
        "indication": "PCI with no significant stenosis",
        "description": "PCI should not be performed in arteries without significant stenosis (>50%)",
        "evidence_level": "Level B-NR",
        "harm": "No benefit, increased complications"
      }
    ]
  },
  "contraindications": {
    "absolute": [
      {
        "contraindication": "No objective evidence of ischemia",
        "description": "PCI not indicated without documented ischemia or symptoms",
        "class": "III (Harm)",
        "evidence_level": "Level B"
      },
      {
        "contraindication": "High surgical risk with favorable CABG anatomy",
        "description": "CABG preferred for left main disease or multivessel disease with diabetes",
        "class": "III (Harm)",
        "evidence_level": "Level A"
      }
    ],
    "relative": [
      {
        "contraindication": "Severe comorbidities limiting life expectancy",
        "description": "PCI not beneficial if life expectancy <1 year",
        "consideration": "Medical management preferred"
      },
      {
        "contraindication": "Contrast allergy",
        "description": "Proceed with premedication if PCI urgent",
        "alternatives": ["Hydrocortisone 200mg IV", "Diphenhydramine 50mg IV", "Consider low-osmolar contrast"]
      }
    ]
  },
  "procedural_recommendations": {
    "access_site": {
      "radial": {
        "class": "Class I",
        "evidence": "Level A",
        "benefits": ["Reduced bleeding", "Lower mortality", "Patient preference", "Earlier ambulation"],
        "recommended_as": "Default access site"
      },
      "femoral": {
        "class": "Class IIa",
        "evidence": "Level B",
        "indications": [
          "Need for large-bore devices (Impella, IABP)",
          "Radial artery spasm or small caliber",
          "Complex bifurcation requiring specific guide support"
        ]
      }
    },
    "antithrombotic_therapy": {
      "antiplatelet": {
        "aspirin": {
          "loading": "325 mg (if not on aspirin)",
          "maintenance": "81 mg daily indefinitely",
          "class": "Class I",
          "evidence": "Level A"
        },
        "p2y12_inhibitors": {
          "clopidogrel": {
            "loading": "600 mg",
            "maintenance": "75 mg daily",
            "duration": "At least 6 months (DES)",
            "class": "Class I",
            "evidence": "Level A"
          },
          "prasugrel": {
            "loading": "60 mg",
            "maintenance": "10 mg daily",
            "duration": "At least 12 months",
            "contraindications": ["Prior stroke/TIA", "Age >75", "Weight <60 kg"],
            "class": "Class I",
            "evidence": "Level B"
          },
          "ticagrelor": {
            "loading": "180 mg",
            "maintenance": "90 mg BID",
            "duration": "At least 12 months",
            "benefits": ["Reduced stent thrombosis", "Reduced MI", "Lower mortality"],
            "risks": ["Increased bleeding", "Dyspnea"],
            "class": "Class I",
            "evidence": "Level A"
          }
        }
      },
      "anticoagulation": {
        "heparin": {
          "class": "Class I",
          "evidence": "Level C",
          "dosing": "70-100 U/kg (target ACT 250-300)",
          "monitoring": "ACT"
        },
        "bivalirudin": {
          "class": "Class IIa",
          "evidence": "Level B",
          "indication": "High bleeding risk",
          "dosing": "0.75 mg/kg bolus, 1.75 mg/kg/h infusion",
          "benefits": ["Lower bleeding", "No monitoring required"]
        },
        "enoxaparin": {
          "class": "IIb",
          "evidence": "Level A",
          "dosing": "0.5 mg/kg IV (optional 0.3 mg/kg SC 12h later)",
          "monitoring": "Not required"
        }
      }
    },
    "stent_selection": {
      "drug_eluting_stents": {
        "class": "Class I",
        "evidence": "Level A",
        "preferred_over": "Bare metal stents",
        "benefits": ["Reduced restenosis", "Reduced TLR", "Reduced TVR"],
        "exceptions": ["Contraindication to DAPT", "High bleeding risk"]
      },
      "bioresorbable_scaffolds": {
        "class": "III (Harm)",
        "evidence": "Level B",
        "description": "Not recommended due to increased thrombosis risk"
      }
    },
    "intravascular_imaging": {
      "ivus": {
        "class": "Class IIa",
        "evidence": "Level A",
        "indications": [
          "Left main PCI",
          "Bifurcation lesions",
          "Stent failure",
          "Uncertain lesion characteristics"
        ],
        "benefits": ["Larger stent expansion", "Lower MACE", "Reduced stent thrombosis"]
      },
      "oct": {
        "class": "Class IIa",
        "evidence": "Level A",
        "indications": [
          "Stent optimization",
          "Plaque characterization",
          "Bifurcation assessment"
        ]
      }
    }
  },
  "special_populations": {
    "diabetes": {
      "recommendation": "Consider CABG for multivessel CAD",
      "class": "Class I",
      "evidence": "Level B",
      "pci_acceptable_if": "Patient prefers PCI, suitable anatomy, low SYNTAX score"
    },
    "chronic_kidney_disease": {
      "contrast_limit": "<3 Ã— baseline creatinine or <100 mL if possible",
      "strategies": [
        "Pre-hydration",
        "N-acetylcysteine (controversial)",
        "Use of radial access to reduce bleeding",
        "Minimize contrast volumes"
      ],
      "class": "Class I",
      "evidence": "Level A"
    },
    "elderly": {
      "age_threshold": ">75 years",
      "considerations": [
        "Bleeding risk (consider shorter DAPT)",
        "Frailty assessment",
        "Comorbidities",
        "Life expectancy",
        "Quality of life goals"
      ],
      "prasugrel_dose": "5 mg daily (if used)",
      "class": "Class IIa",
      "evidence": "Level B"
    },
    "cardiogenic_shock": {
      "mechanical_support": {
        "iabp": {
          "class": "III (No benefit)",
          "evidence": "Level B",
          "note": "Routine use not beneficial"
        },
        "impella": {
          "class": "IIb",
          "evidence": "Level B",
          "consideration": "May be considered in selected patients"
        },
        "va_ecmo": {
          "class": "IIb",
          "evidence": "Level C",
          "consideration": "Rescue therapy for refractory shock"
        }
      }
    }
  },
  "post_procedure_care": {
    "dual_antiplatelet_therapy": {
      "duration": {
        "stable_iskemic_heart_disease": {
          "minimum": "6 months",
          "class": "Class I",
          "evidence": "Level A"
        },
        "acute_coronary_syndrome": {
          "minimum": "12 months",
          "class": "Class I",
          "evidence": "Level A"
        }
      },
      "shorter_dapt": {
        "indication": "High bleeding risk",
        "minimum": "1-3 months",
        "class": "Class IIb",
        "evidence": "Level A",
        "conditions": ["High bleeding risk score", "Acceptable ischemic risk"]
      }
    },
    "follow_up": {
      "schedule": [
        {
          "timeframe": "2 weeks",
          "focus": "Wound check, medication review"
        },
        {
          "timeframe": "30 days",
          "focus": "Symptom assessment, DAPT adherence"
        },
        {
          "timeframe": "12 months",
          "focus": "Functional status, consider cardiac rehab"
        }
      ]
    },
    "secondary_prevention": {
      "statins": {
        "intensity": "High-intensity (atorvastatin 40-80mg or rosuvastatin 20-40mg)",
        "class": "Class I",
        "evidence": "Level A",
        "target_ldl": "<70 mg/dL (preferably <55 mg/dL)"
      },
      "ace_inhibitors": {
        "indication": "LVEF <40%, diabetes, hypertension, CKD",
        "class": "Class I",
        "evidence": "Level A"
      },
      "beta_blockers": {
        "indication": "LVEF <40%, prior MI",
        "class": "Class I",
        "evidence": "Level A"
      }
    }
  },
  "quality_metrics": {
    "core_measures": [
      {
        "metric": "Aspirin at discharge",
        "performance_target": ">99%"
      },
      {
        "metric": "P2Y12 inhibitor at discharge",
        "performance_target": ">99%"
      },
      {
        "metric": "Statin at discharge",
        "performance_target": ">95%"
      },
      {
        "metric": "Door-to-balloon time (STEMI)",
        "performance_target": "<90 minutes in >90% of cases"
      },
      {
        "metric": "Radial access use",
        "performance_target": ">80%"
      }
    ],
    "outcomes": [
      {
        "outcome": "In-hospital mortality",
        "benchmark": "<2% for elective PCI"
      },
      {
        "outcome": "Major bleeding",
        "benchmark": "<2%"
      },
      {
        "outcome": "Stent thrombosis",
        "benchmark": "<1% at 30 days"
      }
    ]
  }
}
